Literature DB >> 21994355

Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B.

Arthur K Turner1, Jonathan C Stephens, Juliet C Beavis, Judith Greenwood, Cornelia Gewert, Roger Randall, Donna Freeman, Michael J Darsley.   

Abstract

Live attenuated oral enterotoxigenic Escherichia coli (ETEC) vaccines have been demonstrated to be safe and immunogenic in human volunteers and to provide a viable approach to provide protection against this important pathogen. This report describes the construction of new ETEC vaccine candidate strains from recent clinical isolates and their characterization. All known genes for ETEC toxins were removed, and attenuating deletion mutations were made in the aroC, ompC, and ompF chromosomal genes. An isolate expressing coli surface antigen 2 (CS2), CS3, heat-labile toxin (LT), heat-stable toxin (ST), and enteroaggregative Escherichia coli heat-stable toxin 1 (EAST1) was attenuated to generate ACAM2007. The subsequent insertion of the operon encoding CS1 created ACAM2017, and this was further modified by the addition of an expression cassette containing the eltB gene, encoding a pentamer of B subunits of LT (LTB), to generate ACAM2027. Another isolate expressing CS5, CS6, LT, ST, and EAST1 was attenuated to generate ACAM2006, from which a lysogenic prophage was deleted to create ACAM2012 and an LTB gene was introduced to form ACAM2022. Finally, a previously described vaccine strain, ACAM2010, had the eltB gene incorporated to generate ACAM2025. All recombinant genes were incorporated into the chromosomal sites of the attenuating mutations to ensure maximal genetic stability. The expression of the recombinant antigens and the changes in plasmids accompanying the deletion of toxin genes are described. Strains ACAM2025, ACAM2022, and ACAM2027 have been combined to create the ETEC vaccine formulation ACE527, which has recently successfully completed a randomized, double-blind, placebo-controlled phase I trial and is currently undergoing a randomized, double-blind placebo-controlled phase II challenge trial, both in healthy adult volunteers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994355      PMCID: PMC3232708          DOI: 10.1128/CVI.05345-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

1.  Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2006-03-17

2.  Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.

Authors:  Robin McKenzie; A Louis Bourgeois; Fayette Engstrom; Eric Hall; H Sunny Chang; Joseph G Gomes; Jennifer L Kyle; Fred Cassels; Arthur K Turner; Roger Randall; Michael Darsley; Cynthia Lee; Philip Bedford; Janet Shimko; David A Sack
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

3.  Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation.

Authors:  Alexandra Daley; Roger Randall; Michael Darsley; Naheed Choudhry; Nicola Thomas; Ian R Sanderson; Nick M Croft; Paul Kelly
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

4.  Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report).

Authors:  G Wiedermann; H Kollaritsch; M Kundi; A M Svennerholm; U Bjare
Journal:  J Travel Med       Date:  2000-01       Impact factor: 8.490

5.  Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.

Authors:  Arthur K Turner; Juliet C Beavis; Jonathan C Stephens; Judith Greenwood; Cornelia Gewert; Nicola Thomas; Alison Deary; Gabriella Casula; Alexandra Daley; Paul Kelly; Roger Randall; Michael J Darsley
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

Review 6.  Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention.

Authors:  Firdausi Qadri; Ann-Mari Svennerholm; A S G Faruque; R Bradley Sack
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

7.  Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin of Escherichia coli.

Authors:  S L Moseley; J W Hardy; M I Hug; P Echeverria; S Falkow
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

Authors:  Sarah A Frech; Herbert L Dupont; A Louis Bourgeois; Robin McKenzie; Jaime Belkind-Gerson; Jose F Figueroa; Pablo C Okhuysen; Norma H Guerrero; Francisco G Martinez-Sandoval; Juan Hm Meléndez-Romero; Zhi-Dong Jiang; Edwin J Asturias; Jane Halpern; Olga R Torres; Ana S Hoffman; Christina P Villar; Raniya N Kassem; David C Flyer; Bo H Andersen; Kazem Kazempour; Sally A Breisch; Gregory M Glenn
Journal:  Lancet       Date:  2008-06-14       Impact factor: 79.321

Review 9.  Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease.

Authors:  Richard I Walker; Duncan Steele; Teresa Aguado
Journal:  Vaccine       Date:  2006-12-19       Impact factor: 3.641

Review 10.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.

Authors:  R Rappuoli; M Pizza; G Douce; G Dougan
Journal:  Immunol Today       Date:  1999-11
View more
  21 in total

1.  A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults.

Authors:  Clayton Harro; David Sack; A Louis Bourgeois; R Walker; Barbara DeNearing; Andrea Feller; Subhra Chakraborty; Charlotte Buchwaldt; Michael J Darsley
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

2.  Multiepitope fusion antigen induces broadly protective antibodies that prevent adherence of Escherichia coli strains expressing colonization factor antigen I (CFA/I), CFA/II, and CFA/IV.

Authors:  Xiaosai Ruan; David E Knudsen; Katie M Wollenberg; David A Sack; Weiping Zhang
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

Review 3.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

4.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

5.  Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.

Authors:  Subhra Chakraborty; Arlo Randall; Tim J Vickers; Doug Molina; Clayton D Harro; Barbara DeNearing; Jessica Brubaker; David A Sack; A Louis Bourgeois; Philip L Felgner; Xiaowu Liang; Sachin Mani; Heather Wenzel; R Reid Townsend; Petra E Gilmore; Michael J Darsley; David A Rasko; James M Fleckenstein
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

Review 6.  [Acute diarrheal disease caused by enteropathogenic Escherichia coli in Colombia].

Authors:  Oscar G Gómez-Duarte
Journal:  Rev Chilena Infectol       Date:  2014-10       Impact factor: 0.520

Review 7.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies.

Authors:  Xiaosai Ruan; Donald C Robertson; James P Nataro; John D Clements; Weiping Zhang
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

9.  Enterotoxigenic Escherichia coli: Orchestrated host engagement.

Authors:  James M Fleckenstein; George M Munson; David A Rasko
Journal:  Gut Microbes       Date:  2013-07-25

Review 10.  Novel antigens for enterotoxigenic Escherichia coli vaccines.

Authors:  James Fleckenstein; Alaullah Sheikh; Firdausi Qadri
Journal:  Expert Rev Vaccines       Date:  2014-04-04       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.